Trevi Therapeutics Revenue

Biotechnology Research • 195 Church Street, 16th Floor, United States • 21-50 Employees

Trevi Therapeutics revenue & valuation

Annual revenue	$14,100,000
Revenue per employee	$336,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$45,100,000
Total funding	$220,100,000

Key Contacts at Trevi Therapeutics

Jordyn Saradhi

Director, R&D Financial Operations

Catherine Weenink

Snr. Director Clinical Operations

Anne Vanlent

Member Board Of Directors. Audit Committee Chair

Lisa Potter

Associate Director

Harpreet Kalia

Director, Clinical Supply Management

Abbey Nakano

Associate Director Medical Affairs

Sally Lam

Senior Director, Head Of Quality Assurance And Compliance

Jonathan Carlson

Associate Director, Fp&A And Accounting Operations

Pam Nieves

Associate Director, Quality Assurance & Compliance

Kevin Fitzmaurice

Senior Director, Technical Operations

Company overview

Headquarters	195 Church Street, 16th Floor, New Haven, CT 06510, US
Phone number	+12033042499
Website	trevitherapeutics.com
NAICS	541714
SIC	283
Founded	2011
Employees	21-50
Socials

Trevi Therapeutics Email Formats

Trevi Therapeutics uses 4 email formats. The most common is {first initial}.{last name} (e.g., j.doe@trevitherapeutics.com), used 63.6% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@trevitherapeutics.com	63.6%
{first name}.{last name}	john.doe@trevitherapeutics.com	22.7%
{first initial}{last name}	jdoe@trevitherapeutics.com	9.1%
{first name}{last name}	johndoe@trevitherapeutics.com	4.5%

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically significant reduction in cough frequency in clinical trials with IPF chronic cough patients and RCC patients. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi is headquartered in New Haven, CT.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Director

Manager

Entry

Employees by Department

Trevi Therapeutics has 30 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Trevi Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-05-07	14	$55,000,000
2025-01-16	14	$50,000,000
2025-07-02	14	$115,100,000

Funding Insights

$220,100,000

Total funding amount

$115,100,000

Most recent funding amount

Number of funding rounds

Trevi Therapeutics Tech Stack

Discover the technologies and tools that power Trevi Therapeutics's digital infrastructure, from frameworks to analytics platforms.

MediaElement.js

Video players

reCAPTCHA

Security

Microsoft 365

jQuery Migrate

JavaScript libraries

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

PHP

Programming languages

WordPress

Blogs

Divi

Page builders

Google Analytics

Analytics

GoDaddy

Hosting

Nginx

Reverse proxies

Frequently asked questions

Trevi Therapeutics is located in 195 Church Street, 16th Floor, US.

You can reach Trevi Therapeutics at +12033042499.

Trevi Therapeutics generates an estimated annual revenue of $14,072,000. This revenue figure reflects the company's market position and business performance in its industry.

Trevi Therapeutics has an estimated valuation of $45,100,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Trevi Therapeutics was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

Trevi Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Trevi Therapeutics has raised a total of $220,100,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.